Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.52 USD

106.52
379,870

-1.99 (-1.83%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $106.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ensign Enhances Presence With 3 New Acquisitions in 2 States

by Zacks Equity Research

ENSG adds three skilled nursing facilities in Idaho and California, boosting its U.S. footprint and fueling future growth.

Zacks Equity Research

Here's Why You Should Hold Cigna Stock in Your Portfolio for Now

by Zacks Equity Research

CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.

Zacks Equity Research

Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit

by Zacks Equity Research

VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.

Zacks Equity Research

BD Stock Might See Short-term Decline After Warning on Tamponade Tubes

by Zacks Equity Research

BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.

Zacks Equity Research

Here's Why You Should Add HealthEquity Stock to Your Portfolio Now

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

VEEV Stock Up as Q1 Earnings & Revenues Beat Estimates, Margin Rise

by Zacks Equity Research

Veeva Systems' fiscal first-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.

Zacks Equity Research

Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer

by Zacks Equity Research

HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.

Zacks Equity Research

NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial

by Zacks Equity Research

NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.

Zacks Equity Research

Reasons to Retain Veeva Systems Stock in Your Portfolio for Now

by Zacks Equity Research

VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Add Pediatrix Medical to Your Portfolio Now

by Zacks Equity Research

MD rises 5.6% YTD as earnings beat, hospital deals and lower costs drive growth. The Zacks Rank #2 signals strong near-term prospects.

Zacks Equity Research

Here's Why Encompass Health Shares Are Attracting Investors Now

by Zacks Equity Research

EHC stock jumps 28.8% YTD as investors rally behind strong earnings beat, raised 2025 guidance and a growing national rehab hospital footprint.

Zacks Equity Research

BioSig Stock Surges Following Share Exchange Deal With Streamex

by Zacks Equity Research

BSGM merges with Streamex to enter the blockchain space, aiming to revolutionize commodity tokenization and expand its footprint in digital asset markets.

Zacks Equity Research

CI's Unit Unveils Offering to Expand Access to GLP-1 Medications

by Zacks Equity Research

Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.

Zacks Equity Research

RVTY Stock Falls Despite the Latest Launch of Automated Instrument

by Zacks Equity Research

Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.

Zacks Equity Research

PacBio Stock Slips Despite New China Distribution Deal With Haorui

by Zacks Equity Research

PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.

Zacks Equity Research

Reasons to Retain TransMedics Stock in Your Portfolio for Now

by Zacks Equity Research

TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.

Zacks Equity Research

Is it Worth Retaining ResMed Stock in Your Portfolio Now?

by Zacks Equity Research

RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.

Zacks Equity Research

ITGR vs. SONVY: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. SONVY: Which Stock Is the Better Value Option?

Zacks Equity Research

AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech

by Zacks Equity Research

Autonomix secures key U.S. patent for its groundbreaking catheter-based nerve-sensing and stimulation tech, aiming to transform treatment across major diseases

Zacks Equity Research

Why Integer (ITGR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

EHC Opens Rehabilitation Unit in Fort Myers, Boosts Florida Footprint

by Zacks Equity Research

Encompass Health inaugurates the Rehabilitation Hospital of Fort Myers in partnership with Lee Health to provide high-quality rehabilitation services across Florida.

Zacks Equity Research

MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio

by Zacks Equity Research

Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.

Zacks Equity Research

BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad

by Zacks Equity Research

Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL continues to witness growth on the back of its strong product portfolio.